FDA anti-infective advisory panel meeting
Executive Summary
FDA's Anti-Infective Drugs Advisory Committee will meet June 2 and 3. On June 2, members will discuss Advanced Life Sciences' cethromycin for the outpatient treatment of adults with mild to moderate community-acquired pneumonia. The June 3 meeting will address the development of drugs to treat tuberculosis and drug-resistant tuberculosis, including diagnosis, treatment duration, study design (such as endpoints and duration of follow-up) and safety issues